AZ's Crestor flubs key heart failure trial

AstraZeneca didn't get its coveted results from the long-awaited CORONA trial. Crestor failed to show any statistically significant benefit in heart failure patients. So Crestor lacks a competitive edge enjoyed by rival Lipitor and generic statins: Trials that show a clear reduction in deaths and heart disease.

It was a long shot, really; heart failure isn't generally considered to be relieved by statins like Crestor. But AZ wanted something different from the old, tried-and-true data that shows the drugs stave off complications from heart disease. A head-to-head trial against Lipitor would have cost beaucoups, and it would have been risky to boot. What if Lipitor had come out ahead?

- take a look at AstraZeneca's press release
- read the analysis from The Wall Street Journal
- read the Hemscott report

Related Articles:
AZ hit with Crestor patent challenge. Report
Crestor less safe than competing statins. Report
Top 5 layoffs of 2007--AstraZeneca. Report
AstraZeneca lays out road map for recovery. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.